Erasca Reports Encouraging Phase 1 Data for ERAS-0015

An announcement from Erasca ( (ERAS) ) is now available.

On April 27, 2026, Erasca reported positive preliminary Phase 1 dose escalation results for its pan-RAS molecular glue ERAS-0015 in RAS-mutant solid tumors, drawing on data from the AURORAS-1 trial in the U.S. and JYP0015M101 in China. The drug showed well-behaved pharmacokinetics, defined a pharmacologically active dose range of 16-32 mg once daily, and achieved substantial reductions in KRAS G12X circulating tumor DNA at these doses, with all 14 evaluated patients showing at least a 75% decline.

Across both studies, ERAS-0015 demonstrated robust monotherapy activity in heavily pretreated KRAS G12X non-small-cell lung cancer, with unconfirmed eight-week overall response rates up to 75% at pharmacologically active doses, and in second-line pancreatic cancer, with unconfirmed 14-week response rates up to 50% at the 32 mg dose. Nearly all responding patients in both tumor types remained on treatment at the data cutoffs in early 2026, underscoring the durability of benefit seen so far.

The safety profile was generally favorable, with mostly low-grade adverse events, no dose-limiting toxicities, low rates of treatment-related dose modifications and no discontinuations due to treatment-related events, although one case of Grade 3 pneumonitis that progressed to death was reported in a pancreatic cancer patient. Based on the totality of Phase 1 data, Erasca selected 24 mg and 32 mg once-daily as recommended monotherapy doses and showed early signs that ERAS-0015 can be combined with the anti-EGFR antibody panitumumab, including an unconfirmed partial response in metastatic colorectal cancer.

Operationally, the company began ERAS-0015 monotherapy expansion and combination dose escalation cohorts in the U.S. ahead of previous guidance, with more detailed monotherapy expansion and combination data now expected in the first half of 2027. Erasca also highlighted progress on its pan-KRAS inhibitor ERAS-4001, with preliminary Phase 1 monotherapy data targeted for the second half of 2026 and plans to start expansion and combination cohorts in 2027, positioning the firm as an emerging player in the competitive RAS-targeted oncology landscape.

The most recent analyst rating on (ERAS) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Erasca stock, see the ERAS Stock Forecast page.

Spark’s Take on ERAS Stock

According to Spark, TipRanks’ AI Analyst, ERAS is a Neutral.

The score is held back primarily by weak financial fundamentals (no revenue, ongoing large losses, and material cash burn). Offsetting factors include a strong technical uptrend and positive corporate developments that extend cash runway and add a near-term clinical milestone, while valuation remains challenging due to negative earnings and no dividend support.

To see Spark’s full report on ERAS stock, click here.

More about Erasca

Erasca, Inc. is a biotechnology company focused on developing targeted oncology therapies for patients with RAS- and KRAS-mutant solid tumors. Its pipeline includes agents such as ERAS-0015, a pan-RAS molecular glue, and ERAS-4001, a pan-KRAS inhibitor, aimed at cancers including colorectal cancer, non-small-cell lung cancer and pancreatic adenocarcinoma, which together represent large, high-need patient populations in the U.S.

Average Trading Volume: 5,251,589

Technical Sentiment Signal: Buy

Current Market Cap: $6.68B

For an in-depth examination of ERAS stock, go to TipRanks’ Overview page.